Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Darifenacin (Primary) ; Fesoterodine (Primary) ; Imidafenacin (Primary) ; Mirabegron (Primary) ; Oxybutynin (Primary) ; Propiverine (Primary) ; Solifenacin (Primary) ; Tolterodine (Primary) ; Trospium chloride (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 01 Oct 2019 Status changed from active, no longer recruiting to completed.
- 31 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Sep 2019.
- 31 Jul 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Sep 2019.